🚀 VC round data is live in beta, check it out!
Novanta Valuation Multiples
Discover revenue and EBITDA valuation multiples for Novanta and similar public comparables like Envista Holdings, Lepu Medical Technology, Ottobock, GRG Banking and more.
Novanta Overview
About Novanta
Novanta Inc supplies core technology solutions to medical, life science, and advanced industrial OEMs, leveraging proprietary expertise in precision medicine, precision manufacturing, robotics and automation, and advanced surgery. It has two segments: Automation Enabling Technologies and Medical Solutions. Automation Enabling Technologies, which generates the majority of revenue, provides laser beam steering and scanning solutions, laser sources, and robotic and precision motion technologies. The Medical Solutions segment provides medical-grade technologies, including medical insufflators, endoscopic pumps, and integrated operating room technologies. The company operates in the United States, Germany, and other markets, with revenue generated from the United States.
Founded
1970
HQ
Employees
3.0K
Website
Financials (LTM)
EV
$5B
Novanta Financials
Novanta reported last 12-month revenue of $1000M and EBITDA of $229M.
In the same LTM period, Novanta generated $455M in gross profit, $229M in EBITDA, and $64M in net income.
Revenue (LTM)
Novanta P&L
In the most recent fiscal year, Novanta reported revenue of $981M and EBITDA of $221M.
Novanta expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1000M | XXX | $981M | XXX | XXX | XXX |
| Gross Profit | $455M | XXX | $435M | XXX | XXX | XXX |
| Gross Margin | 46% | XXX | 44% | XXX | XXX | XXX |
| EBITDA | $229M | XXX | $221M | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 23% | XXX | XXX | XXX |
| EBIT Margin | 18% | XXX | 17% | XXX | XXX | XXX |
| Net Profit | $64M | XXX | $54M | XXX | XXX | XXX |
| Net Margin | 6% | XXX | 5% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Novanta Stock Performance
Novanta has current market cap of $5B, and enterprise value of $5B.
Market Cap Evolution
Novanta's stock price is $128.85.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5B | $5B | 0.0% | XXX | XXX | XXX | $1.51 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNovanta Valuation Multiples
Novanta trades at 4.5x EV/Revenue multiple, and 19.7x EV/EBITDA.
EV / Revenue (LTM)
Novanta Financial Valuation Multiples
As of April 19, 2026, Novanta has market cap of $5B and EV of $5B.
Equity research analysts estimate Novanta's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Novanta has a P/E ratio of 71.4x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5B | XXX | $5B | XXX | XXX | XXX |
| EV (current) | $5B | XXX | $5B | XXX | XXX | XXX |
| EV/Revenue | 4.5x | XXX | 4.6x | XXX | XXX | XXX |
| EV/EBITDA | 19.7x | XXX | 20.5x | XXX | XXX | XXX |
| EV/EBIT | 25.4x | XXX | 26.5x | XXX | XXX | XXX |
| EV/Gross Profit | 9.9x | XXX | 10.4x | XXX | XXX | XXX |
| P/E | 71.4x | XXX | 85.4x | XXX | XXX | XXX |
| EV/FCF | 55.8x | XXX | 93.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Novanta Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Novanta Margins & Growth Rates
Novanta's revenue in the last 12 month grew by 7%.
Novanta's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Novanta's rule of 40 is 30% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Novanta's rule of X is 40% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Novanta Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | 12% | XXX | 13% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 30% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 40% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 10% | XXX | 10% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 32% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Novanta Public Comps
See public comps and valuation multiples for other Medical Devices and Automation & Robotics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Novanta | XXX | XXX | XXX | XXX | XXX | XXX |
| Envista Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| Lepu Medical Technology | XXX | XXX | XXX | XXX | XXX | XXX |
| Ottobock | XXX | XXX | XXX | XXX | XXX | XXX |
| GRG Banking | XXX | XXX | XXX | XXX | XXX | XXX |
| Jiangsu Yuyue Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Novanta M&A Activity
Novanta acquired XXX companies to date.
Last acquisition by Novanta was on XXXXXXXX, XXXXX. Novanta acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Novanta
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialNovanta Investment Activity
Novanta invested in XXX companies to date.
Novanta made its latest investment on XXXXXXXX, XXXXX. Novanta invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Novanta
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Novanta
| When was Novanta founded? | Novanta was founded in 1970. |
| Where is Novanta headquartered? | Novanta is headquartered in United States. |
| How many employees does Novanta have? | As of today, Novanta has over 3K employees. |
| Who is the CEO of Novanta? | Novanta's CEO is Matthijs Glastra. |
| Is Novanta publicly listed? | Yes, Novanta is a public company listed on Nasdaq. |
| What is the stock symbol of Novanta? | Novanta trades under NOVT ticker. |
| When did Novanta go public? | Novanta went public in 1999. |
| Who are competitors of Novanta? | Novanta main competitors are Envista Holdings, Lepu Medical Technology, Ottobock, GRG Banking. |
| What is the current market cap of Novanta? | Novanta's current market cap is $5B. |
| What is the current revenue of Novanta? | Novanta's last 12 months revenue is $1000M. |
| What is the current revenue growth of Novanta? | Novanta revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Novanta? | Current revenue multiple of Novanta is 4.5x. |
| Is Novanta profitable? | Yes, Novanta is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Novanta? | Novanta's last 12 months EBITDA is $229M. |
| What is Novanta's EBITDA margin? | Novanta's last 12 months EBITDA margin is 23%. |
| What is the current EV/EBITDA multiple of Novanta? | Current EBITDA multiple of Novanta is 19.7x. |
| What is the current FCF of Novanta? | Novanta's last 12 months FCF is $81M. |
| What is Novanta's FCF margin? | Novanta's last 12 months FCF margin is 8%. |
| What is the current EV/FCF multiple of Novanta? | Current FCF multiple of Novanta is 55.8x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.